Guangzhou Baiyunshan Pharmaceutical Holdings Crescita futura
Future criteri di controllo 1/6
Guangzhou Baiyunshan Pharmaceutical Holdings prevede che gli utili e i ricavi cresceranno rispettivamente di 11.3% e 6.8% all'anno. Si prevede che l'EPS crescerà di 4.1% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 10.2% in 3 anni.
Informazioni chiave
11.3%
Tasso di crescita degli utili
4.1%
Tasso di crescita dell'EPS
| Healthcare crescita degli utili | 20.9% |
| Tasso di crescita dei ricavi | 6.8% |
| Rendimento futuro del capitale proprio | 10.2% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 29 Oct 2024 |
Aggiornamenti recenti sulla crescita futura
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Recorded A 7.9% Miss On Revenue: Analysts Are Revisiting Their Models
Oct 29
Earnings Report: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Missed Revenue Estimates By 8.1%
Sep 04Recent updates
Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Shareholders Have More To Worry About Than Only Soft Earnings
Nov 01Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Recorded A 7.9% Miss On Revenue: Analysts Are Revisiting Their Models
Oct 29Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Oct 17Here's What's Concerning About Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns On Capital
Sep 25Earnings Report: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Missed Revenue Estimates By 8.1%
Sep 04A Look At The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Jul 15Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
Jun 26Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227
Jun 03The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon
May 23Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
May 13Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?
Mar 08Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price
Feb 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward
Feb 10Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Jan 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing
Jan 09With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Nov 28A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 15We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Oct 19Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes
Oct 03Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?
Aug 15Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall
Jul 02Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jun 01Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors
May 01The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing
Mar 28Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Feb 23With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Jan 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger
Dec 24Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 24Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?
Nov 11Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year
May 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price
Apr 29Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Apr 10We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Jan 09Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet
Oct 11Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jul 12Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All
May 26How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?
Apr 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate
Apr 08These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well
Mar 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain
Feb 11
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?
Jan 26Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?
Jan 06Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet
Dec 23Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 09Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Nov 26Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2026 | 88,532 | 4,416 | N/A | 3,638 | 4 |
| 12/31/2025 | 82,556 | 3,940 | N/A | 4,306 | 6 |
| 12/31/2024 | 75,871 | 3,545 | N/A | 5,146 | 2 |
| 9/30/2024 | 76,391 | 3,423 | 1,167 | 2,451 | N/A |
| 6/30/2024 | 76,588 | 3,794 | 1,374 | 2,808 | N/A |
| 3/31/2024 | 76,833 | 4,105 | 2,092 | 3,804 | N/A |
| 12/31/2023 | 75,515 | 4,056 | 2,475 | 4,104 | N/A |
| 9/30/2023 | 74,167 | 4,283 | 2,958 | 4,601 | N/A |
| 6/30/2023 | 73,538 | 4,188 | 2,954 | 4,546 | N/A |
| 3/31/2023 | 71,878 | 4,069 | 1,898 | 3,242 | N/A |
| 12/31/2022 | 70,788 | 3,967 | 5,615 | 6,999 | N/A |
| 9/30/2022 | 70,280 | 3,883 | 1,805 | 3,187 | N/A |
| 6/30/2022 | 70,106 | 3,807 | 3,878 | 5,201 | N/A |
| 3/31/2022 | 69,507 | 3,898 | 3,606 | 4,910 | N/A |
| 12/31/2021 | 69,014 | 3,720 | 4,419 | 5,673 | N/A |
| 9/30/2021 | 68,329 | 3,568 | 4,862 | 5,982 | N/A |
| 6/30/2021 | 67,333 | 3,653 | 4,133 | 5,174 | N/A |
| 3/31/2021 | 64,735 | 3,359 | 4,726 | 5,674 | N/A |
| 12/31/2020 | 61,674 | 2,915 | -291 | 585 | N/A |
| 9/30/2020 | 61,774 | 2,688 | 3,526 | 4,389 | N/A |
| 6/30/2020 | 62,081 | 2,406 | 2,641 | 3,543 | N/A |
| 3/31/2020 | 63,881 | 2,966 | 2,041 | 4,414 | N/A |
| 12/31/2019 | 64,952 | 3,189 | 2,623 | 5,022 | N/A |
| 9/30/2019 | 62,420 | 3,161 | 563 | 2,884 | N/A |
| 6/30/2019 | 60,735 | 3,370 | 911 | 3,088 | N/A |
| 3/31/2019 | 53,380 | 3,943 | 1,003 | 1,616 | N/A |
| 12/31/2018 | 42,234 | 3,441 | 4,738 | 5,217 | N/A |
| 9/30/2018 | 34,863 | 4,015 | 3,077 | 3,378 | N/A |
| 6/30/2018 | 24,679 | 3,523 | N/A | 2,171 | N/A |
| 3/31/2018 | 22,575 | 2,482 | N/A | 2,280 | N/A |
| 1/1/2018 | 20,954 | 2,062 | N/A | 1,834 | N/A |
| 9/30/2017 | 20,459 | 1,937 | N/A | 1,888 | N/A |
| 6/30/2017 | 20,294 | 1,834 | N/A | 1,649 | N/A |
| 3/31/2017 | 20,273 | 1,583 | N/A | 2,157 | N/A |
| 12/31/2016 | 20,036 | 1,508 | N/A | 2,545 | N/A |
| 9/30/2016 | 19,598 | 1,397 | N/A | 2,806 | N/A |
| 6/30/2016 | 19,502 | 1,357 | N/A | 2,427 | N/A |
| 3/31/2016 | 19,442 | 1,345 | N/A | 2,442 | N/A |
| 12/31/2015 | 19,125 | 1,300 | N/A | 1,942 | N/A |
| 9/30/2015 | 19,244 | 1,300 | N/A | 1,499 | N/A |
| 6/30/2015 | 19,270 | 1,295 | N/A | 1,859 | N/A |
| 3/31/2015 | 18,876 | 1,241 | N/A | 1,827 | N/A |
| 12/31/2014 | 18,818 | 1,194 | N/A | 1,749 | N/A |
| 9/30/2014 | 19,049 | 1,106 | N/A | 1,902 | N/A |
| 6/30/2014 | 18,563 | 1,067 | N/A | 1,136 | N/A |
| 3/31/2014 | 18,130 | 1,036 | N/A | 895 | N/A |
| 12/31/2013 | 17,608 | 980 | N/A | 1,336 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: La crescita prevista degli utili di 874 ( 11.3% all'anno) è superiore al tasso di risparmio ( 2.3% ).
Guadagni vs Mercato: Si prevede che gli utili di 874 ( 11.3% all'anno) cresceranno più lentamente rispetto al mercato Hong Kong ( 11.6% all'anno).
Guadagni ad alta crescita: Si prevede che gli utili di 874 cresceranno, ma non in modo significativo.
Ricavi vs Mercato: Si prevede che il fatturato di 874 ( 6.8% all'anno) crescerà più lentamente rispetto al mercato Hong Kong ( 7.8% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di 874 ( 6.8% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che il Return on Equity di 874 sarà basso tra 3 anni ( 10.2 %).